GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: A clinical and translational study

F. Pietrantonio, R. Berenato, C. A. Maggi, M. Caporale, M. Milione, F. Perrone, E. Tamborini, D. Baratti, S. Kusamura, L. Mariani, Monica Niger, Alessia Mennitto, A. Gloghini, I. Bossi, G. Settanni, A. Busico, P.F. Bagnoli, M. Di Bartolomeo, M. Deraco, F. de Braud

Research output: Contribution to journalArticlepeer-review

Cite this